616 related articles for article (PubMed ID: 26922358)
1. Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis.
Iannone A; Losurdo G; Pricci M; Girardi B; Massaro A; Principi M; Barone M; Ierardi E; Di Leo A
J Gastrointest Cancer; 2016 Jun; 47(2):143-51. PubMed ID: 26922358
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia.
Lidgard GP; Domanico MJ; Bruinsma JJ; Light J; Gagrat ZD; Oldham-Haltom RL; Fourrier KD; Allawi H; Yab TC; Taylor WR; Simonson JA; Devens M; Heigh RI; Ahlquist DA; Berger BM
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1313-8. PubMed ID: 23639600
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests.
Meklin J; Syrjänen K; Eskelinen M
Anticancer Res; 2020 Feb; 40(2):575-581. PubMed ID: 32014898
[TBL] [Abstract][Full Text] [Related]
4. Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT).
Heigh RI; Yab TC; Taylor WR; Hussain FT; Smyrk TC; Mahoney DW; Domanico MJ; Berger BM; Lidgard GP; Ahlquist DA
PLoS One; 2014; 9(1):e85659. PubMed ID: 24465639
[TBL] [Abstract][Full Text] [Related]
5. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
[TBL] [Abstract][Full Text] [Related]
6. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
Dollinger MM; Behl S; Fleig WE
Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
Sharma T
Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
[TBL] [Abstract][Full Text] [Related]
8. Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests.
Meklin J; SyrjÄnen K; Eskelinen M
Anticancer Res; 2020 Jul; 40(7):3591-3604. PubMed ID: 32620599
[TBL] [Abstract][Full Text] [Related]
9. Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
Klepp P; Kisiel JB; Småstuen MC; Røseth A; Andersen SN; Vatn MH; Ahlquist DA; Moum BA; Brackmann S
Scand J Gastroenterol; 2018 Mar; 53(3):273-278. PubMed ID: 29313389
[TBL] [Abstract][Full Text] [Related]
10. A novel multitarget stool DNA test for colorectal cancer screening.
Malik P
Postgrad Med; 2016; 128(2):268-72. PubMed ID: 26753807
[TBL] [Abstract][Full Text] [Related]
11. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
12. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model.
Baxter NT; Koumpouras CC; Rogers MA; Ruffin MT; Schloss PD
Microbiome; 2016 Nov; 4(1):59. PubMed ID: 27842559
[TBL] [Abstract][Full Text] [Related]
13. Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities.
Bailey JR; Aggarwal A; Imperiale TF
Gut Liver; 2016 Mar; 10(2):204-11. PubMed ID: 26934885
[TBL] [Abstract][Full Text] [Related]
14. USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing.
Berger BM; Parton MA; Levin B
Am J Manag Care; 2016 Feb; 22(2):e77-81. PubMed ID: 26881323
[TBL] [Abstract][Full Text] [Related]
15. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of quantification based on novel evaluation with stool DNA and fecal immunochemical test for colorectal cancer detection.
Xu H; Chen H; Hu J; Xiong Z; Li D; Wang S; Yu J
BMC Gastroenterol; 2022 Aug; 22(1):384. PubMed ID: 35963995
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive fecal testing for colorectal cancer.
Zou J; Xiao Z; Wu Y; Yang J; Cui N
Clin Chim Acta; 2022 Jan; 524():123-131. PubMed ID: 34756863
[TBL] [Abstract][Full Text] [Related]
18. Multitarget stool DNA testing for colorectal-cancer screening.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
[TBL] [Abstract][Full Text] [Related]
19. Screening for colon cancer: A test for occult blood.
Khakimov N; Khasanova G; Ershova K; Gibadullina L; Vetkina T; Lobisheva G; Chumakova A
Int J Risk Saf Med; 2015; 27 Suppl 1():S110-1. PubMed ID: 26639687
[TBL] [Abstract][Full Text] [Related]
20. Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.
Levin TR; Corley DA; Jensen CD; Marks AR; Zhao WK; Zebrowski AM; Quinn VP; Browne LW; Taylor WR; Ahlquist DA; Lidgard GP; Berger BM
Dig Dis Sci; 2017 Mar; 62(3):678-688. PubMed ID: 28044229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
